{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000722","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.468296+00:00","generated_at":"2026-05-23T01:12:24.251147+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"medium","headline":"Channel Therapeutics issues NYSE American-required announcement on going concern in 2024 10-K","bullets":["2024 10-K audit opinion includes a going concern emphasis of matter (previously filed March 27, 2025).","Press release issued May 1, 2025 to comply with NYSE American Sections 401(h) and 610(b).","Announcement does not change or amend the audited financial statements or the 2024 10-K.","Company develops non-opioid pain therapeutics (no new business updates)."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000722","json":"https://secwatch.observer/filing/0001753926-25-000722.json","markdown":"https://secwatch.observer/filing/0001753926-25-000722.md","text":"https://secwatch.observer/filing/0001753926-25-000722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625000722/0001753926-25-000722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625000722/g084795_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:12:24.251147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001698530-26-000060","ticker":"XCUR","company_name":"EXICURE, INC.","filed_at":"2026-06-01T19:30:08+00:00","headline":"Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-26-000060","json":"https://secwatch.observer/filing/0001698530-26-000060.json","markdown":"https://secwatch.observer/filing/0001698530-26-000060.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000060/0001698530-26-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000060/xcur-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-054956","ticker":"MSS","company_name":"Maison Solutions Inc.","filed_at":"2026-05-12T17:22:23+00:00","headline":"Maison Solutions regains Nasdaq minimum bid price compliance; listing continues","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.2,"calibrated_materiality_score":0.2,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054956","json":"https://secwatch.observer/filing/0001213900-26-054956.json","markdown":"https://secwatch.observer/filing/0001213900-26-054956.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1892292/000121390026054956/0001213900-26-054956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1892292/000121390026054956/ea0290261-8k_maison.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-067517","ticker":"CLIR","company_name":"ClearSign Technologies Corp","filed_at":"2026-05-28T20:19:02+00:00","headline":"ClearSign Technologies suspends ATM prospectus supplement for $10.39 million common stock offering; no shares sold","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-067517","json":"https://secwatch.observer/filing/0001104659-26-067517.json","markdown":"https://secwatch.observer/filing/0001104659-26-067517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434524/000110465926067517/0001104659-26-067517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434524/000110465926067517/tm2615697d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001665988-26-000029","ticker":"BVS","company_name":"Bioventus Inc.","filed_at":"2026-05-21T20:58:18+00:00","headline":"Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance","event_type":"regulatory","sec_items":["7.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001665988-26-000029","json":"https://secwatch.observer/filing/0001665988-26-000029.json","markdown":"https://secwatch.observer/filing/0001665988-26-000029.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/0001665988-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/bvs-20260521.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-056656","ticker":"AIRE","company_name":"reAlpha Tech Corp.","filed_at":"2026-05-14T20:20:34+00:00","headline":"reAlpha regains Nasdaq minimum bid price compliance; matter closed","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same SEC item: 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-056656","json":"https://secwatch.observer/filing/0001213900-26-056656.json","markdown":"https://secwatch.observer/filing/0001213900-26-056656.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859199/000121390026056656/0001213900-26-056656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859199/000121390026056656/ea0290935-8k_realpha.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026519","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-01T11:00:24+00:00","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026519","json":"https://secwatch.observer/filing/0001493152-26-026519.json","markdown":"https://secwatch.observer/filing/0001493152-26-026519.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}